Sapience Therapeutics Revenue and Competitors

Scarsdale, NY USA

Location

#3103

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Sapience Therapeutics's estimated annual revenue is currently $5.1M per year.(i)
  • Sapience Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Sapience Therapeutics has 33 Employees.(i)
  • Sapience Therapeutics grew their employee count by 22% last year.

Sapience Therapeutics's People

NameTitleEmail/Phone
1
Founder, President and CEOReveal Email/Phone
2
Chief Financial OfficerReveal Email/Phone
3
Chief Medical OfficerReveal Email/Phone
4
SVP Translational Pharmacology, Head Research at Sapience Therapeutics, Inc.Reveal Email/Phone
5
SVP CMC and OperationsReveal Email/Phone
6
Chief Administrative Officer & ControllerReveal Email/Phone
7
Principal ScientistReveal Email/Phone
8
Associate ScientistReveal Email/Phone
9
Lab Manager/Senior Research AssociateReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-20%N/AN/A
#2
$6.7M438%N/AN/A
#3
$34.4M222-1%N/AN/A
#4
$5.2M670%$10MN/A
#5
$2M130%N/AN/A
#6
$7.5M370%$51.6MN/A
#7
$0.3M2-50%N/AN/A
#8
$4.3M21-16%$3.3MN/A
#9
$3.6M230%N/AN/A
#10
$4.3M56-8%$118MN/A
Add Company

What Is Sapience Therapeutics?

Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma multiforme (GBM), which is the most severe and deadly form of brain cancer. Our strategy is to develop novel therapeutic agents that dramatically improve patient survival in high mortality cancers. We seek to develop therapies that have synergistic or additive effects with current therapies, and we intend to develop our drugs to be used in combination with other approved cancer treatments. Elements of our strategy include: - Development of our lead product candidate, ST-36, in GBM, the most severe form of brain cancer, initially to improve response rates and progression-free survival in combination with existing standards of care - Assessment of the impact of ST-36 on additional tumor types - Evaluation of in-licensing opportunities that fit our oncology and high unmet need focus to potentially expand our pipeline

keywords:N/A

N/A

Total Funding

33

Number of Employees

$5.1M

Revenue (est)

22%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Sapience Therapeutics News

2022-04-13 - Sapience Therapeutics Presents Late-Breaking Data at AACR ...

Sapience Therapeutics Presents Late-Breaking Data at AACR 2022 Demonstrating the Potential of Targeting Intracellular Interactions to Drug...

2022-03-30 - Sapience Therapeutics Expands Executive Team with ...

Sapience Therapeutics Expands Executive Team with Appointment of Gina Capiaux, Ph.D. as Vice President, Regulatory Affairs.

2022-03-22 - Peptide Therapeutics: Contract API Manufacturing Market ...

Since the discovery of insulin, the peptide therapeutics market has ... Santhera Pharmaceuticals; Sapience Therapeutics; SBS Genetech...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.5M336%N/A
#2
$5.1M408%N/A
#3
$7.3M400%N/A
#4
$10.6M405%N/A
#5
$6.9M420%N/A